Picks report for 2022 was just released, and this is your chance to be
among the first wave of investors to see this coveted list of 100+ handpicked
stocks. For nearly 40 years, MoneyShow has surveyed the nation’s most respected
and well-known financial newsletter experts to provide you with a well-rounded
and diverse shopping list of investment ideas to outperform the markets. From
conservative quality blue chips to high-growth stocks with massive potential
upside, this is one of the most anticipated reports on the market every year,
and it’s yours FREE
My top picks for 2022
report came from our mid-cap “Best Months” stock basket. We issued our
“Best Months” Seasonal MACD Buy Signal on October 8, 2021, and then ran our
fundamental screens and published our picks on October 14.
With large cap stocks dominating the market for much of this
bull run we focused on the lower end of the market capitalization spectrum.
Small caps ranged from $50 million to $1 billion in market cap with mid-caps in
the $1 to 5 billion range. My two top picks for 2022 come from this mid-cap
group. We screen for reasonably solid valuations, revenue and earnings growth
and relatively low price-to-sales and price-to-earnings ratios. Then we look
for positive price and volume action as well as other constructive technical
and chart pattern indications. Finally, we lean towards stocks flying under
Wall Street’s radar with a below average number of analysts following them.
A10 Networks (ATEN) was added to our newsletter
portfolio on October 15 at 13.30.
Pacira BioSciences (PCRX) was added to our newsletter
portfolio on October 18 at 52.89.
A10 Networks is leading provider of secure cloud
application services and solutions for on-premises, multi-cloud and edge-cloud
environments at hyperscale. ATEN enables service providers and enterprises to
deliver business-critical applications that are secure and efficient for
multi-cloud transformation and 5G readiness. Their products and services help
future-proof infrastructures so their customers can provide the most secure and
available digital experience. Their portfolio of state-of-the-art solutions
optimize, accelerate, and secure applications and networks for enterprises,
service providers, and government organizations. Growing both organically with
existing clients and adding new business ATEN exhibits a strong balance sheet
and solid growth potential.
Pacira BioSciences is the leading provider of
non-opioid pain management and regenerative health solutions. The firm is also
developing innovative interventions to address debilitating conditions
involving the sympathetic nervous system, such as cardiac electrical storm,
chronic pain, and spasticity. Pacira has three commercial-stage non-opioid
treatments: EXPAREL®, a long-acting, local analgesia currently approved for
postsurgical pain management; ZILRETTA®, an extended-release, intra-articular,
injection indicated for the management of osteoarthritis knee pain, and iovera,
a novel, handheld device for delivering immediate, long-acting, drug-free pain
control using precise, controlled doses of cold temperature to a targeted nerve.
The company is actively expanding its portfolio with acquisition and boasts a
solid balance sheet with strong growth and relatively reasonable valuations for
a drug company.
Our Top Picks for 2021 performed nicely. Avid Technology (AVID) was up 122% in
2021, but the digital media pioneer was closed out of our newsletter portfolio
on August 4, a 132% in the portfolio. Peripheral vascular disease treatment and
solution provider LeMaitre Vascular (LMAT) remains in our portfolio and was up 28% in 2021.